Independent research on the U.S. markets, Baptista Research

Baptista Research

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. 

We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>Acadia Healthcare reported its fourth quarter and full-year 2025 financial results, demonstrating modest revenue growth and operational expansion amidst ongoing challenges.</li><li>For the quarter, the company recorded $821.5 million in revenue, a 6.1% increase year-over-year, and adjusted EBITDA of $99.8 million.</li><li>Full-year revenue reached $3.31 billion, a 5% increase that slightly surpassed the upper end of prior guidance, while adjusted EBITDA totaled $608.9 million, near the guidance range's upper boundary.</li></ul>

Acadia Healthcare reported its fourth quarter and full-year 2025 financial results, demonstrating modest revenue growth and operational expansion amidst ongoing challenges.For the quarter, the company recorded $821.5 million in revenue, a 6.1% increase year-over-year, and adjusted EBITDA of $99.8 million.Full-year revenue reached $3.31 billion, a 5% increase that slightly surpassed the upper end of prior guidance, while adjusted EBITDA totaled $608.9 million, near the guidance range's upper boundary.

아카디아 헬스케어: 33억 1천만 달러 규모로 성장세를 이어가던 기업, 운영상의 제약에 직면하다!

Acadia Healthcare Co

아카디아 헬스케어: 33억 1천만 달러 규모로 성장세를 이어가던 기업, 운영상의 제약에 직면하다!